Compare GDOT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDOT | AVXL |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.3M | 635.6M |
| IPO Year | 2010 | N/A |
| Metric | GDOT | AVXL |
|---|---|---|
| Price | $13.00 | $3.68 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.00 | ★ $22.00 |
| AVG Volume (30 Days) | 1.2M | ★ 4.2M |
| Earning Date | 11-10-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,007,128,000.00 | N/A |
| Revenue This Year | $22.03 | N/A |
| Revenue Next Year | $11.64 | $141.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.16 | N/A |
| 52 Week Low | $6.13 | $2.86 |
| 52 Week High | $15.41 | $14.44 |
| Indicator | GDOT | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 28.04 |
| Support Level | $10.42 | $3.00 |
| Resistance Level | $12.64 | $4.05 |
| Average True Range (ATR) | 0.56 | 0.59 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 98.29 | 18.11 |
Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for today's workforce.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.